BUSINESS
SSP Looks to Broaden Switch OTC Portfolio under New President
SSP is looking to expand its portfolio of switch OTC medicines — nonprescription drugs converted from prescription status — in Japan by leveraging the global capabilities of parent Opella, newly appointed president Yoko Motoshima said in a recent interview. “We…
To read the full story
Related Article
- SSP Appoints Yoko Motoshima as New President
March 16, 2026
- SSP to Roll Out Pharmacist Training Ahead of OTC Cialis Launch in Japan
October 1, 2025
BUSINESS
- Kyorin Starts Pivotal Study of Chronic Cough DTx in Japan
June 12, 2026
- Lotte Biopharma CVC Invests in Swiss ADC Startup
June 12, 2026
- Ono Seeks Velexbru Nod for CNS Involvement of Malignant Lymphoma
June 12, 2026
- Ono Files Opdivo for Anaplastic Thyroid Cancer
June 12, 2026
- Lilly Warns Against Off-Label Use of Mounjaro
June 11, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





